TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Clinically meaningful improvement in the overall response rate (ORR)—the trial’s primary endpoint—was seen across each TIGIT cohort, with a 63.3% ORR reported for group A, a 65.6% ORR seen ...

The number of TIGIT-focused programs in development has nearly doubled in the past few years, growing from 13 in 2017 to 25 in 2020, according to the Cancer Research Institute.

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study ...

iTeos is the latest, but perhaps most high-profile casualty, of a faltering anti-TIGIT landscape. Until this point, only drug candidates had primarily been lost, as opposed to entire biotechs.

TIGIT is an immunosuppressive mediator found on immune cells in the microenvironment of many tumors. Merck and Roche have shown adding anti-TIGIT antibodies to PD-1/L1 checkpoint inhibitors ...

The mechanism has proven challenging, with GSK and iTeos becoming the latest companies to terminate an anti-TIGIT asset. Last month, BeiGene announced it was terminating development of ociperlimab ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) ...

But TIGIT has not lived up to the hype, at least not yet. The most recent setback occurred just last week, when Roche reported the failure of its anti-TIGIT antibody in a Phase 3 study involving ...

Maybe TIGIT really isn't all that useful as an oncology target, and the absolute best case for it is that it crawls up to clinical significance if you manage to align everything perfectly.

iTeos Therapeutics focuses on developing immuno-oncology treatments for cancer patients, with a focus on TIGIT-targeted therapies. Roche's accidental disclosure of positive data on its anti-TIGIT ...

–Detailed Results Will Be Presented on December 20 at 3 pm ET/ 12 pm PT during the ASCO Monthly Plenary Series–. FOSTER CITY, Calif.& HAYWARD, Calif.---- Gilead Sciences, Inc. and Arcus ...